Incidence of immune checkpoint inhibitor–mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score–matched retrospective study
Background and aims The risk of use of immune-mediated diarrhea and colitis (imDC) in patients with preexisting inflammatory bowel disease (IBD) is not fully understood. We report the incidence of imDC in these patients, and compare with a matched cohort of patients with cancer and without IBD.Metho...
Saved in:
| Main Authors: | Wei Wei, Pauline Funchain, Ravi Shah, Joseph Sleiman, Muhammad Salman Faisal, Jessica Philpott |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-06-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/9/6/e002567.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Immune Checkpoint Inhibitor Use in Microscopic Colitis
by: Natalie Farha, et al.
Published: (2022-06-01) -
Preexisting ulcerative colitis increases the risk of immune-related colitis and predicts divergent survival outcomes in gastrointestinal cancer patients treated with immune checkpoint inhibitors
by: Shuo Xu, et al.
Published: (2025-08-01) -
New Presentation of Takayasu Arteritis in a Patient With Preexisting Ulcerative Colitis
by: Elliot C. Smith, et al.
Published: (2024-06-01) -
Comparison of Prognostic Risk Models (IMDC, MSKCC, CFF) in Patients Diagnosed with Metastatic Renal Cell Cancer
by: Merve KESKİNKILIÇ, et al.
Published: (2025-08-01) -
Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases
by: Pankti Reid, et al.
Published: (2023-12-01)